Type of Study: Clinical Trial

Sponsor / Support: ABCSG, ALLIANCE

Primary Objectives: To compare invasive disease-free survival (iDFS) for the combination of at least 5 years of endocrine therapy plus 2 years of palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR-positive/HER2-negative early breast cancer (EBC).

Design: This is a prospective, international, multicenter, randomized, open label Phase III study evaluating the addition of 2 years of palbociclib to at least 5 years of standard adjuvant endocrine therapy for patients with HR+/ HER2-negative EBC.

Sample Size: 4.600 patients

Principal Investigator: Gustavo Werutsky (Steering Committee – LACOG)

Countries LATAM: Mexico